ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.
Hiukka A, Ståhlman M, Pettersson C, Levin M, Adiels M, Teneberg S, Leinonen ES, Hultén LM, Wiklund O, Oresic M, Olofsson SO, Taskinen MR, Ekroos K, Borén J.
Diabetes. 2009 Sep;58(9):2018-26. Epub 2009 Jun 5.PMID: 19502413 [PubMed - indexed for MEDLINE]Related articlesFree article